Literature DB >> 9596394

Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke.

F Reiter1, M Danni, G Lagalla, G Ceravolo, L Provinciali.   

Abstract

OBJECTIVE: To evaluate the efficacy of a combined treatment for spastic foot using selective injections of botulinum toxin (BTA) into the tibialis posterior muscle followed by ankle taping, and to compare it with current BTA treatment procedure.
DESIGN: Single-blind randomized control trial. Three-month follow-up after treatment.
SETTING: Neurorehabilitation clinic.
SUBJECTS: Eighteen outpatients with equinovarus foot due to severe spasticity after stroke.
INTERVENTIONS: (1) Injection of 190 to 320 BTA U into several calf muscles (group A); (2) injection of 100 BTA U into the tibialis posterior muscle, followed by ankle-foot taping (group B). MAIN OUTCOME MEASURES: Ankle range of motion (ROM), Ashworth scale, gait velocity, and step length.
RESULTS: Average Ashworth scores decreased 1 point in both groups, but the benefit appeared of shorter duration in group B. Changes in both foot position at rest and passive ankle ROM were observed in all patients, without treatment-related differences, except for gain in passive dorsiflexion that appeared higher in group A. Gait velocity and step length showed similar increases in both groups.
CONCLUSION: The combination of selective injections of low BTA doses with ankle-foot taping is as effective as the injection of the current doses for the reduction of foot inversion with positive effects on gait parameters.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9596394     DOI: 10.1016/s0003-9993(98)90068-5

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  19 in total

1.  [Botulinum toxin in the treatment of adult spasticity. An interdisciplinary German 10-point consensus 2010].

Authors:  J Wissel; M auf dem Brinke; M Hecht; C Herrmann; M Huber; S Mehnert; I Reuter; A Schramm; A Stenner; C van der Ven; M Winterholler; A Kupsch
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

2.  Botulinum toxin improves reduced dorsiflexion after Achilles tendon surgery.

Authors:  Iris Reuter; Olaf Lorbach; Sabine Mehnert; Manfred Kaps; Martin Engelhardt
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2009-10-14       Impact factor: 4.342

Review 3.  Botulinum toxin treatment of adult spasticity : a benefit-risk assessment.

Authors:  Geoffrey Sheean
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 4.  Botulinum toxin A treatment of adult upper and lower limb spasticity.

Authors:  S Hesse; B Brandi-Hesse; A Bardeleben; C Werner; M Funk
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 5.  Spasticity treatment with botulinum toxins.

Authors:  A B Ward
Journal:  J Neural Transm (Vienna)       Date:  2008-04-04       Impact factor: 3.575

Review 6.  Poststroke motor dysfunction and spasticity: novel pharmacological and physical treatment strategies.

Authors:  Stefan Hesse; Cordula Werner
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

7.  Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey.

Authors:  Nicola Smania; Carlo Colosimo; Anna Rita Bentivoglio; Giorgio Sandrini; Alessandro Picelli
Journal:  Funct Neurol       Date:  2013 Oct-Dec

8.  Effectiveness of matrix-rhythm therapy on increased muscle tone, balance and gait parameters in stroke survivors: a single-blinded, randomized, controlled clinical trial.

Authors:  Ayse Unal; Filiz Altug; Gulsum Tikac; Ugur Cavlak
Journal:  Acta Neurol Belg       Date:  2020-06-14       Impact factor: 2.396

Review 9.  Botulinum toxin in poststroke spasticity.

Authors:  Suheda Ozcakir; Koncuy Sivrioglu
Journal:  Clin Med Res       Date:  2007-06

Review 10.  Stretch for the treatment and prevention of contractures.

Authors:  Lisa A Harvey; Owen M Katalinic; Robert D Herbert; Anne M Moseley; Natasha A Lannin; Karl Schurr
Journal:  Cochrane Database Syst Rev       Date:  2017-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.